Short Interest in NexImmune, Inc. (NASDAQ:NEXI) Decreases By 49.4%

NexImmune, Inc. (NASDAQ:NEXI) was the target of a large decline in short interest in March. As of March 31st, there was short interest totalling 17,800 shares, a decline of 49.4% from the March 15th total of 35,200 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 2.3% of the company’s stock are short sold.

NexImmune Trading Up 9.3 %

NEXI opened at $3.96 on Thursday. The firm’s fifty day simple moving average is $6.92 and its 200 day simple moving average is $5.41. NexImmune has a 12 month low of $1.25 and a 12 month high of $28.69. The stock has a market capitalization of $4.19 million, a P/E ratio of -0.09 and a beta of 1.84.

Institutional Investors Weigh In On NexImmune

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James & Associates bought a new stake in NexImmune during the 1st quarter worth about $87,000. Sei Investments Co. bought a new stake in NexImmune during the 2nd quarter worth about $43,000. Goldman Sachs Group Inc. bought a new stake in NexImmune during the 2nd quarter worth about $47,000. Renaissance Technologies LLC lifted its position in NexImmune by 44.7% during the 1st quarter. Renaissance Technologies LLC now owns 73,661 shares of the company’s stock worth $310,000 after buying an additional 22,761 shares in the last quarter. Finally, Envestnet Asset Management Inc. bought a new stake in NexImmune during the 1st quarter worth about $31,000. 9.85% of the stock is owned by institutional investors.

NexImmune Company Profile

NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.